NCT02224820View on ClinicalTrials.gov

Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Chronic Kidney Disease
Interventions
BIOLOGICAL

IdeS

Doses are administered in ascending doses

Trial Locations (1)

75185

Dept. of Transplant Surgery, Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

Hansa Biopharma AB
All Listed Sponsors
lead

Hansa Biopharma AB

INDUSTRY

NCT02224820 - Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease | Biotech Hunter | Biotech Hunter